Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07525141 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-1761981 in Participants With Solid Tumors
A Phase 1 study, sponsored by Johnson & Johnson Enterprise Innovation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT07525141: Recruiting Phase 1 study, sponsored by Johnson & Johnson Enterprise Innovation.
NCT07525141 is a Phase 1 study that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07525141, a Phase 1 study, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
Primary Outcome
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive interv
Interventions
- DRUG Cetrelimab
- DRUG JNJ-1761981
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 1 |
What NCT07525141 shows while recruiting
NCT07525141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which Cetrelimab is the first listed.
NCT07525141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07525141 about?
NCT07525141 is a clinical study titled "A Study of JNJ-1761981 in Participants With Solid Tumors". The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
What is the current status of trial NCT07525141?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2026-05-18. Estimated completion is 2029-01-31.
What interventions are being tested in trial NCT07525141?
The interventions under investigation include: Cetrelimab (DRUG), JNJ-1761981 (DRUG).
Who is sponsoring clinical trial NCT07525141?
This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07525141's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI